Strategic objectives

• Development of new therapies for the prevention of bronchopulmonary dysplasia.
• Evaluation of new therapies in PAH.
• Evaluation of new drugs in paediatrics.
• Prognosis and quality of life in congenital heart disease in the medium and long term.
• Genetic mapping of type 1 diabetes mellitus.
• Development, implementation and dissemination of new technologies in type 1 diabetes mellitus in childhood and adolescence. 
• New insulins in type 1 diabetes mellitus in childhood and adolescence.
• Lifestyle habits, prevention and treatment in childhood obesity.
• Epidemiology and genetic analysis of rare diseases: pseudohypoparathyroidism (Spanish PHP GROUP), monogenic diabetes.
• Epidemiological studies of efficacy and safety in children treated with growth hormone.
• Hyperandrogenism and type 1 diabetes.

Research lines

• Pulmonary arterial hypertension.
• Cell therapy in bronchopulmonary dysplasia.
• Markers for predicting the risk of developing bronchopulmonary dysplasia.
• Safety of new drugs in the paediatric population.
• Adolescent and adult congenital heart disease.
• New technologies in type 1 diabetes.
• New drugs in type 1 diabetes in childhood and adolescence.
• Epidemiology and safety of paediatric hospital infections.
• Hyperandrogenism and type 1 diabetes mellitus.
• Pituitary tumours in children and adolescents.
• New imaging techniques in congenital cardiopathies.
• New techniques in pulmonary valve implantation.